Navigation Links
Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
Date:7/23/2008

European Patent Office Notifies Company of Intent to Grant Patent

LONDON, July 23 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, today announces new intellectual property cover for its lead product, Atu027. The European Patent Office announced on July 17, 2008 that it intends to grant a European patent covering Silence's lead internal product candidate. This patent will give Silence broad exclusivity not only for Atu027, but for any siRNA targeting protein kinase N beta.

The notice is based on European patent application EP 03 790 894.4. The claims deemed allowable by the European Patent Office are directed to various aspects of the use of protein kinase N beta, the gene target of Atu027. Among others, the claims are related to any siRNA molecule, including Atu027, directed against protein kinase N beta for use in the treatment of numerous cancers involving the PI3-kinase pathway. Other claims are related to the use of protein kinase N beta for screening purposes and its use as a downstream target of the PI3-kinase pathway.

Atu027 is a proprietary AtuRNAi molecule currently in development for solid cancer indications, including gastrointestinal and lung cancers. The candidate is designed to silence the function of a novel kinase protein involved in tumour growth and metastases and utilizes Silence Therapeutics's proprietary drug delivery system AtuPLEX to deliver active drug into the appropriate cells following systemic administration.

"The protection of targets through composition of matter patents is an important part of our patent strategy," said Iain Ross, Chairman and CEO of Silence Therapeutics. "The notice of intent to grant represents a significant step forward for the Group in both its own programs and those of its collaborators, as it provides intellectual property cover not only for the Company's lead product, Atu027, but also broad exclusivity for any siRNA t
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
6. Botaneco obtains $2.4 million in funding from AVAC
7. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
8. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
9. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
10. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
11. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/15/2014)... ANNAPOLIS, Md. , Sept. 15, 2014  The ... will be celebrated October 12-18. A joint initiative of ... its member companies , IPAW is designed to: ... collection , Recognize the contributions of plasma donors ... about lifesaving plasma protein therapies and rare diseases ...
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual Information ... from 12:00 to 1:00 p.m. EDT. The session will ... practice-oriented instruction, designed for working professionals. Participants will also ... career in the biotechnology industry. , If interested in ... UMBC’s Biotechnology Graduate Programs, UMBC offers a variety of ...
(Date:9/14/2014)... particularly ingenious when it comes to survival strategies. They ... hostile environment, for example during treatment with antibiotics. A ... a protective slime capsule consisting of sugar chains and ... have for the first time created a detailed three-dimensional ... blocks cross the bacterial cell wall, a crucial step ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2New insights in survival strategies of bacteria 2
... , , BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 ... AMGN ) today announced that they entered into an agreement ... including ARRY-403, currently being tested in a Phase 1 clinical trial ... terms of the agreement, Array will receive an upfront payment of ...
... , , JUPITER, Fla., Dec. ... today that it has extended its collaboration with The Scripps ... to re-annotate the genome of Dyadic,s patented and proprietary C1 ... successful relationship between the two organizations which began in March ...
... , ROCKAWAY, N.J., Dec. 14 ... Evidence-Based Approach , published by the Infusion ... anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications ... in the treatment of various types of cancer since the ...
Cached Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
(Date:9/15/2014)... hearing and cognitive function may play roles in one,s ... rhythm, pitch, timbre, tone durations, and formal structure in ... article explain that extremes in musical aptitude (extreme capacity/no ... of individuals having moderate aptitude. , "This is a ... underlying genes, and it is influenced to varying degrees ...
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... Sharks, swamps and a tropical rainforest teeming with life ... Yorkshire, England. But for the first time evidence of Doncaster,s ... discovered in a derelict mining tip. , Some of the ... and as well as the egg case, several horseshoe crabs ... All had been preserved in rocks that formed within ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2'Jaws' lived in Doncaster 2
... its wood and cottony fibers, the kapok tree now ... for decades: the notion that African and South American ... million years ago. , Research by University of Michigan ... perhaps other rainforest--trees colonized Africa after the continents split ...
... modification to successfully manipulate the growth in height of trees, ... similar to normal trees – but after several years of ... few inches. , This is a “proof of concept” that ... It opens the door to a wide variety of new ...
... that will be published online in advance of its July ... colleagues (The Salk Institute and HHMI) demonstrate that endosomes can ... animals. , "These findings will influence our thinking of the ... why cells use them as signaling compartments," noted lead author ...
Cached Biology News:The kapok connection -- Study explains rainforest similarities 2Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3
... for use as a wash buffer for Michels ... is useful for transportation of specimens (such as ... Samples may remain in Transport Fluid for ... Michels Transport Fluid is not a fixative and ...
... use with 96- or 384-well PCR plates Dimples ... location on 96-tube plates End tabs on Thermo-Mat™ ... plate* Efficient sealing is achieved with either Thermo-Mat™ ... or clip-down hot lid thermal cyclers Fully autoclavable ...
... TUNEL-based assay kit provides complete components including ... detection of DNA fragmentation in cultured cells ... in the procedure provides greater sensitivity than ... analyzed by flow cytometry. The kit works ...
... Buffer is a unique alternative to ... (TRIS acetate-EDTA) electrophoresis buffers. Bionic Buffer ... rapid running times, and high-resolution band ... gel electrophoresis after dilution to working ...
Biology Products: